ASCENDIS PHARMA A/S - ADR (ASND)

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024

COPENHAGEN, Denmark, April 25, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2024 financial...

United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

COPENHAGEN, Denmark, April 24, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United Kingdom’s Medicines &...

Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024

COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a...

Interesting ASND Put And Call Options For March 15th

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

Launch of TransCon™ PTH underway with full commercial availability in Germany and Austria; U.S. PDUFA date of May 14, 2024TransCon CNP pivotal ApproaCH...

Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the...

Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024

COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results...

Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism

COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide, developed...

Ascendis, Frazier launch new ophthalmology company called Eyconis (NASDAQ:ASND)

Ascendis Pharma (ASND) said it and investment firm Frazier Life Sciences have spun out Ascendis’s TransCon ophthalmology assets as a separate company called Eyc

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life...

Ascendis Pharma Introduces Vision 2030

Strategic roadmap to achieve blockbuster status for multiple products and expand the Company’s engine for future innovation COPENHAGEN,...

Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries

/PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) has added three new endocrinology therapies to its specialist...

Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief...

Jefferies starts Ascendis at buy, cites TransCon PTH market potential (NASDAQ:ASND)

Jefferies initiated coverage of Ascendis Pharma (ASND) with a buy rating, expecting FDA approval for TransCon PTH for hypoparathyroidism by May 14. Read more here.

Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week

TransCon CNP is the first investigational product to demonstrate improvements in health-related quality of life and disease impacts in children with...

TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

–   On primary efficacy and key secondary endpoints, TransCon hGH demonstrated statistically significant reduction from baseline in trunk fat and increase...

FDA accepts Ascendis resubmission of TransCon PTH market application (NASDAQ:ASND)

Ascendis (ASND) said the FDA has accepted its resubmitted market application for TransCon PTH in the treatment of hypoparathyroidism, with a decision expected by May 14. Read more.

FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

– PDUFA goal date is May 14, 2024 COPENHAGEN, Denmark, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the...

Bullish Two Hundred Day Moving Average Cross - ASND

Ascendis Pharma signs license agreement with Teijin in Japan (NASDAQ:ASND)

Ascendis Pharma has entered into a license agreement with Teijin Limited for the development of rare disease treatments in Japan, receiving upfront payment...

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan

–   Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan –   Ascendis Pharma...

Ascendis receives EU approval for hypoparathyroidism drug (NASDAQ:ASND)

Ascendis Pharma has received EU approval for its drug palopegteriparatide, also known as Yorvipath and TransCon PTH, for the treatment of chronic hypoparathyroidism in adults.

Citi opens 30-day catalyst watch on Ascendi ahead of FDA feedback (NASDAQ:ASND)

Citi said it has opened a 30-day catalyst watch for Ascendi Pharma (ASND) ahead of expected FDA feedback on the company's resubmitted application for the drug TransCon PTH.

Ascendis resubmits FDA application for hypoparathyroidism drug (ASND)

Ascendis Pharma (ASND) has resubmitted its New Drug Application to the FDA for TransConPTH in the treatment of hypoparathyroidism. Read more here.